• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu
VIEW ALL RESEARCH-GROUP

Molecular signaling
Viñals’s lab

DESCRIPTION

Our research is focused on the study of the implication of intracellular signaling cascades driving to pathological situations in cancer and vascular diseases.

The molecular signaling cascades that take place inside the cells are essential to respond to changes in their environment or to alter their homeostasis, for example, at the level of cell proliferation, movement, growth or metabolism. Understanding how these mechanisms of signal transduction work can explain how biological processes are controlled in a normal physiological context, but also, the alterations that take place in many pathologies. Our group investigates this in two pathological contexts: The first is ovarian epithelial cancer, where we study the pathways involved in metastasis and the mechanisms of resistance to therapies. A second context is a rare vascular disease, HHTs, in which, in collaboration with the group led by Toni Riera (Hospital de Bellvitge), we study which signaling pathways are altered in patients with mutations that cause this disease, and how treat them with new drugs.

Group members

Francesc Viñals

Group leaders

Group Leader

Agnès Figueras

Researchers

Núria Gendrau Sanclemente

PhD student

Ferran Medina Jover

PhD student

José Luís Rocamora

PhD student

Tianyu Dai

PhD student

Publications

Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

24 de June de 2024/in Viñals's lab/by

Nat Commun. 2024 Jun 24;15(1):5352. doi: 10.1038/s41467-024-49718-8. ABSTRACT Immune checkpoint blockade (ICB) approaches have changed the therapeutic landscape for many tumor types. However, half of cutaneous squamous cell carcinoma (cSCC) patients remain unresponsive or develop resistance. Here, we show that, during cSCC progression in male mice, cancer cells acquire epithelial/mesenchymal plasticity and change their immune […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-06-24 10:00:002024-06-24 10:00:00Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread

27 de November de 2023/in Viñals's lab/by miguel

Mol Oncol. 2023 Nov 27. doi: 10.1002/1878-0261.13556. Online ahead of print. ABSTRACT High-grade serous ovarian cancer (HGSOC) is the deadliest gynecological malignancy. The most common form of metastatic spread of HGSOC is transcoelomic dissemination. In this process, detached cells from the primary tumor aggregate as tumorspheres and promote the accumulation of peritoneal ascites. This represents […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-11-27 11:00:002023-11-27 11:00:00Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread

New genetic drivers in hemorrhagic hereditary telangiectasia

9 de September de 2023/in Viñals's lab/by miguel

Eur J Intern Med. 2023 Sep 7:S0953-6205(23)00308-4. doi: 10.1016/j.ejim.2023.08.024. Online ahead of print. ABSTRACT BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease inherited in an autosomal dominant manner. Disease-causing variants in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are detected in around 90% of the patients; also 2% of […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-09-09 10:00:002023-09-09 10:00:00New genetic drivers in hemorrhagic hereditary telangiectasia

Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases

24 de May de 2023/in Viñals's lab/by miguel

Eur J Intern Med. 2023 Sep;115:10-17. doi: 10.1016/j.ejim.2023.05.020. Epub 2023 May 22. ABSTRACT Biomarkers are new tools framed in precision and personalized medicine. Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic vascular disease with disturbances in the angiogenic pathways. Descriptive evidence supports that some angiogenesis-related molecules are differently detected in HHT patients compared to healthy […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-24 10:00:002023-05-24 10:00:00Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases

Feasibility of extended ultrasound examination of the fetal brain between 24 and 37 weeks’ gestation in low-risk pregnancies

17 de April de 2023/in Viñals's lab/by miguel

J Perinat Med. 2023 Apr 18;51(6):815-822. doi: 10.1515/jpm-2022-0605. Print 2023 Jul 26. ABSTRACT OBJECTIVES: To assess the feasibility of identifying fetal brain structures and anatomic landmarks included in the anterior complex (AC) and posterior complex (PC), as well as the proximal hemisphere (PH). METHODS: This was a prospective observational multicenter study of healthy pregnant women […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-17 10:00:002023-04-17 10:00:00Feasibility of extended ultrasound examination of the fetal brain between 24 and 37 weeks’ gestation in low-risk pregnancies
Page 3 of 23‹12345›»

Research Projects

– Ref: PID2020-117815RB-I00 Title: El perfil metabólico como una oportunidad terapéutica en el cáncer epitelial de ovario. implicaciones en metástasis y resistencia a los tratamientos. DGICYT, MINECO. 2021-2024. 217.800 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

– Ref: SAF2017-85869-R Title: Mecanismos de señalización y control metabólico implicados en la diseminación y quimioresistencia en cáncer epitelial de ovario. DGICYT, MINECO. 2018-2020. 181.500 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

Collaborations

Peter B. Vermeulen, University of Antwerp and GZA Hospitals, Belgium
Artur Mezheyeuski, VHIO, Barcelona
Pnina Brodt, Mc Gill University, Montreal, Canada
and Liver Metastases Research Network members

Viñals's lab
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Casanovas’ LabCasanovas's Lab
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}